Intrathecal enzyme replacement therapy: Successful treatment of brain disease via the cerebrospinal fluid
Patricia Dickson(Washington University in St. Louis), Emil Kakkis(BioMarin (United States)), Merry Passage(University of California, Los Angeles), Maryn Peinovich(UCLA Medical Center), Beth Levy(Saint Louis University), Carole Vogler(University of Washington), Steven Q. Le(UCLA Medical Center), Stephen R. Hanson(Oregon Health & Science University), Michael F. McEntee(Knoxville College)
Cited by 162
Related Papers
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma
|Science|2007|648
Three dimensional optical angiography
|Optics Express|2007|631
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|507
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364